Today: 29 April 2026
Browse Category

NYSE:HPE 9 July 2025 - 17 November 2025

AI Hype vs Reality: HPE Stock’s Wild October Ride and What’s Next for Investors

AI Hype vs Reality: HPE Stock’s Wild October Ride and What’s Next for Investors

Hewlett Packard Enterprise stock fell sharply after issuing cautious 2026 guidance on Oct. 15, projecting 5–10% revenue growth, well below Wall Street’s expectations. Shares dropped over 8% before rebounding to around $23–$24. HPE announced a 10% dividend hike and a $3 billion buyback. The company recently closed its $14 billion Juniper Networks acquisition.
22 October 2025
···
HPE Stock Soars and Dips: Inside Hewlett Packard Enterprise’s Wild October Ride

HPE Stock Soars and Dips: Inside Hewlett Packard Enterprise’s Wild October Ride

Hewlett Packard Enterprise shares fell 5–7% after hours on Oct. 15 following cautious FY2026 guidance, despite a recent 52-week high of $26.44 and a 16% year-to-date gain. The company announced a 10% dividend increase and $3 billion in new buybacks at its analyst meeting. Q3 revenue rose 19% to $9.14 billion, but EPS missed forecasts. HPE’s AI tech was recently licensed by Nokia for telecom automation.
16 October 2025
·
High-Performance Computing Highlights (June–July 2025): Exascale Era, HPC-AI Convergence, and Global Supercomputing Advances

High-Performance Computing Highlights (June–July 2025): Exascale Era, HPC-AI Convergence, and Global Supercomputing Advances

El Capitan at Lawrence Livermore National Lab topped the June 2025 TOP500 list with 1.742 exaFLOPS on HPL. Frontier at Oak Ridge ranked second with 1.353 exaFLOPS, followed by Aurora at Argonne with 1.012 exaFLOPS. JUPITER Booster debuted at #4, and Microsoft Azure’s Eagle placed fifth. Europe had three systems in the Top 10.
9 July 2025
·····
1 2

Stock Market Today

  • Sensex Rallies 609 Points as Nifty Nears 24,200 on Strong Earnings and Geopolitical Hope
    April 29, 2026, 9:39 AM EDT. Indian benchmark indices rebounded Wednesday with the BSE Sensex rising 609 points (0.79%) to 77,496.36 and the NSE Nifty climbing 182 points (0.76%) to 24,177.65. Gains were broad-based, led by FMCG, auto, and telecom stocks. Maruti Suzuki surged nearly 3% following a record annual net profit, lifted by highest-ever sales and GST rate cuts. Positive earnings reports and easing geopolitical tensions fueled investor sentiment despite elevated crude oil prices which rose 2.85% to $114.4 a barrel. Asian markets also closed higher, reflecting a global mood shift. However, European and U.S. markets remained subdued. Analysts noted improved corporate performance and hopes of reduced global conflicts helped offset macroeconomic concerns and contributed to today's rebound.

Latest article

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

29 April 2026
Cambridge, Massachusetts, April 29, 2026, 09:04 EDT Biogen Inc. cut its full-year profit outlook on Wednesday, taking some shine off a first-quarter earnings beat driven by stronger sales of its Alzheimer’s drug Leqembi and newer rare-disease medicines. The Cambridge, Massachusetts-based drugmaker now expects 2026 adjusted earnings of $14.25 to $15.25 a share, down $1 at both ends of its prior range. Biogen said the cut reflects acquired in-process research and development charges, meaning costs tied to buying or licensing drug programs that are still being developed and have not yet become commercial products. (marketscreener.com) The revision matters because Biogen is
Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop